Martingale Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Martingale Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-46,904	Closed	-$516K	–	799
2023 Q1	$516K	Buy	46,904 +3,700	+9%	+$53.5K	0.01%	608
2022 Q4	$639K	Buy	43,204 +16,096	+59%	+$281K	0.01%	576
2022 Q3	$519K	Buy	+27,108	New	+$614K	0.01%	613
2022 Q1	–	Sell	-23,111	Closed	-$481K	–	803
2021 Q4	$481K	Buy	23,111 +11,308	+96%	+$225K	0.01%	652
2021 Q3	$282K	Buy	+11,803	New	+$269K	﹤0.01%	764
2021 Q2	–	Sell	-7,208	Closed	-$209K	–	828
2021 Q1	$209K	Buy	+7,208	New	+$225K	﹤0.01%	813

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Martingale Asset Management's ARQT Position: Q2 2023 in Review

Martingale Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 46,904 shares — an estimated $516K sold.

Martingale Asset Management first reported a position in ARQT in Q1 2021 and held it in 6 quarters. The position peaked at $639K in Q4 2022. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

Martingale Asset Management reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Martingale Asset Management sold 46,904 Arcutis Biotherapeutics shares in Q2 2023, an estimated $516K.
Martingale Asset Management first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 6 quarters.
Martingale Asset Management's Arcutis Biotherapeutics position peaked at $639K in Q4 2022.
136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Martingale Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.